Monogenetic Disease Therapy Market Analysis Covering Growth Drivers And Future Outlook

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Monogenetic Disease Therapy Market Projected To Reach By 2030?

The monogenetic disease therapy market has experienced substantial growth in recent years. Projections indicate its expansion from $28.3 billion in 2025 to $31.08 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.8%. Historically, this growth can be attributed to progress in human genome research, the initiation of early gene therapy trials, an increase in rare disease diagnoses, orphan drug incentives, and advancements in viral vectors.

The monogenetic disease therapy market size is anticipated to undergo swift expansion over the next few years. It is forecast to achieve a valuation of $45.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.0%. This projected growth during the forecast period is primarily driven by the advancement of gene editing platforms, the proliferation of rare disease pipelines, higher rates of genetic screening, increased financing for personalized therapy, and wider regulatory approvals. Significant developments expected in this period encompass single gene targeted therapies, programs for gene replacement treatment, RNA-based genetic treatments, gene correction for rare diseases, and the design of precision genetic drugs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33229&type=smp

Which Strong Drivers Are Impacting The Monogenetic Disease Therapy Market Growth?

The monogenetic disease therapy market is projected to see growth driven by the increasing adoption of precision and personalized medicine. This medical approach customizes disease prevention, diagnosis, and treatment according to an individual’s unique genetic, molecular, or lifestyle characteristics to optimize therapeutic efficacy and reduce adverse effects. The rising demand for precision and personalized medicine comes from healthcare providers and patients who seek tailored treatments that achieve maximum therapeutic benefit, minimize side effects, and address individual genetic, molecular, or lifestyle traits. Monogenetic disease therapy supports this by targeting a patient’s specific genetic mutation, enabling highly customized and effective interventions. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, stated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a significant rise from six in 2022. Therefore, the expanding embrace of precision and personalized medicine is fueling the expansion of the monogenetic disease therapy market.

Which Segment Types Are Examined In The Monogenetic Disease Therapy Market Segment Study?

The monogenetic disease therapy market covered in this report is segmented –

1) By Therapy Type: Pharmacological; Surgical; Blood Transfusion; Gene Therapies; Other Therapy Types

2) By Inheritance Pattern: Autosomal; Chromosomal

3) By Application: Cystic Fibrosis; Sickle Cell Anemia; Phenylketonuria; Other Applications

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

5) By End-Users: Clinics; Hospitals; Diagnostic Centres; Home Healthcare; Other End-Users

Subsegments:

1) By Pharmacological: Small Molecule Drugs; Enzyme Replacement Therapies; Protein Replacement Therapies; Immunomodulatory Drugs; Targeted Molecular Therapies

2) By Surgical: Organ Transplant Procedures; Tissue Repair Surgeries; Gene Editing Assisted Surgeries; Minimally Invasive Surgeries; Corrective Surgical Interventions

3) By Blood Transfusion: Red Blood Cell Transfusions; Platelet Transfusions; Plasma Transfusions; Stem Cell Infusions; Autologous Blood Transfusions

4) By Gene Therapies: Ex Vivo Gene Therapy; In Vivo Gene Therapy; Viral Vector Based Gene Therapy; Non Viral Vector Gene Therapy; Genome Editing Based Therapy

5) By Other Therapy Types: Cell Based Therapies; RNA Based Therapies; Protein Based Therapies; Combination Therapies; Experimental Therapies

Which Trends Are Contributing To Changes In The Monogenetic Disease Therapy Market?

Major companies in the monogenetic disease therapy market are concentrating on developing innovative gene therapies, such as Duchenne muscular dystrophy (DMD)–targeted protocols, to slow disease progression and improve long-term patient outcomes. Duchenne muscular dystrophy–targeted protocols are structured clinical or therapeutic guidelines specifically designed to diagnose, monitor, and manage patients with Duchenne muscular dystrophy, focusing on slowing disease progression, improving muscle function, and addressing associated complications. As an example, in January 2026, Sarepta Therapeutics Inc, a US-based biopharmaceutical company, launched Elevidys for ambulatory patients aged four and older with DMD, reporting up to a 73% reduction in the rate of functional decline over three years compared with an external control group, underscoring the importance of early intervention to alter the disease course and improve quality of life.

Which Players Are Part Of The Competitive Landscape Of The Monogenetic Disease Therapy Market?

Major companies operating in the monogenetic disease therapy market are Pfizer Inc., Sanofi S.A., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics Inc., Ptc therapeutics inc., Crispr therapeutics ag, CRISPR Therapeutics, Voyager Therapeutics Inc., Oxford Biomedica plc, REGENXBIO INC., Arcturus therapeutics holdings inc., Editas medicine Inc., American Gene Technologies, UniQure NV., MeiraGTx Limited, Prime medicine, Abeona therapeutics Inc., Blue Cross Blue Shield Association, Rocket pharmaceuticals Inc.

Get The Full Monogenetic Disease Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/monogenetic-disease-therapy-market-report

Which Geographic Region Dominates The Monogenetic Disease Therapy Market?

North America was the largest region in the monogenetic disease therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monogenetic disease therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Monogenetic Disease Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33229&type=smp

Browse Through More Reports Similar to the Global Monogenetic Disease Therapy Market 2026, By The Business Research Company

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795